South Korean sci-fi bestseller inks six-figure film deal with Warner Bros
Cheon Seon-ran's 'A Thousand Blues' to be adapted into Hollywood film
Cheon Seon-ran's heartwarming science fiction novel "A Thousand Blues" is headed for the big screen in the US.
Hubble, the literary imprint of Seoul-based East-Asia Publishing, said Saturday that it had signed a film adaptation deal with Warner Bros. Pictures, and that the novel is "now on track to meet a global audience on screen."
The Hollywood studio behind blockbuster franchises such as Harry Potter and Dune, is said to have been drawn to the novel's "original and compelling" storytelling.
Directors including Celine Song ("Past Lives"), Greta Gerwig ("Little Woman," "Barbie") and Alfonso Cuaron ("Roma," "Gravity") are among the candidates being considered for the adaptation, according to the publisher.
Set in 2035, "A Thousand Blues" imagines a near future where humanoid robots have become part of everyday life. At its heart is the story of Collie, a humanoid jockey, and its racehorse, Today. Both are nearing the end of their usefulness as Today faces euthanasia due to failing joints.
Their journey toward an uncertain future becomes entwined with that of a mother and her two daughters, who step in to help. The novel explores themes of grief, healing and what it means to slow down in a world obsessed with speed and performance.
First published in 2020, "A Thousand Blues" is Cheon's debut novel. It won the Grand Prize at the 4th Korea Science Fiction Awards and became a runaway bestseller, with over 200,000 copies sold in Korea to date.
The translation rights have been sold to more than 10 countries, with recent publications in Japan, Germany, Taiwan, China and the United Kingdom.
"A Thousand Blues" was also adapted for the stage: produced as a play by the National Theater Company of Korea and as a musical by the Seoul Performing Arts Company in 2024.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
HCLTech Grant Americas second edition awards $1 million to three NGOs to create scalable solutions to combat climate change
NEW YORK and NOIDA, India, June 6, 2025 /PRNewswire/ -- HCLTech (NSE: (BSE: a leading global technology company, announced Osa Conservation as the winner and Daily Acts and Ocean Wise as the two runners-up of the second edition of the HCLTech Climate Action Grant in the Americas. The three non-government organizations (NGOs) will be awarded a total of $1 million to help build scalable, sustainable solutions to drive climate action across the Americas. In the second year, applications increased by more than 70%, and after several rounds of review and rigorous due diligence, HCLTech selected Osa Conservation to receive $500,000 and Daily Acts and Ocean Wise to receive $250,000 each. This year's registrations increased by 34% from the 10 eligible countries across the Americas, including Argentina, Brazil, Canada, Colombia, Costa Rica, Guatemala, Mexico, Panama, Peru and the U.S. Osa Conservation, based in Costa Rica, will focus its grant award on Climate Lifeboat corridors, which help species migrate and thrive amid climate change. By reconnecting fragmented tropical habitats, the project supports climate adaptation while safeguarding ecosystems across millions of acres. California-based Daily Acts will use its grant for its community-powered climate resilience initiative. The project blends government strategy with grassroots action to advance water management, stormwater mitigation and social infrastructure across neighborhoods in Petaluma, Calif. and beyond. Canada-based Ocean Wise will dedicate its grant to its kelp forest restoration project on the Pacific coast. By managing urchin overpopulation and combining advanced technology and ecological research, the project aims to strengthen marine biodiversity and support coastal communities. "We are excited to support this year's recipients of the HCLTech Grant Americas as they expand their innovative projects to reconnect natural habitats, boost community resilience and rejuvenate marine ecosystems across the Americas," said Dr. Nidhi Pundhir, Senior Vice President, Global CSR, HCLTech. "This year, we saw a substantial increase in applications, highlighting the urgency of mitigating the adverse effects of climate change and the importance of supporting initiatives that pave the way for a sustainable future." In its inaugural year in 2023, HCLTech Climate Action Grant in the Americas committed $5 million in grants over five years to support sustainable solutions to fight the climate crisis across the Americas. The Grant in the Americas builds on HCLTech and the HCLFoundation (HCLTech's CSR arm) focus on continuous global sustainability commitment with a total investment of over $175 million in CSR programs to date. HCLTech is consistently recognized for its commitment to making a positive difference in the environment. Through our technology and collective expertise, HCLTech was recognized as an Industry Mover by S&P Global Sustainability Yearbook 2023 for sustainable business practices and continues to partner with leading U.S.-based organizations, including Feeding America and Girl Up, to serve the broader community. For more information on HCLTech Climate Action Grant in the Americas, its mission and the application process, please visit HCLTech is a global technology company, home to more than 223,000 people across 60 countries, delivering industry-leading capabilities centered around digital, engineering, cloud and AI, powered by a broad portfolio of technology services and products. We work with clients across all major verticals, providing industry solutions for Financial Services, Manufacturing, Life Sciences and Healthcare, High Tech, Semiconductor, Telecom and Media, Retail and CPG and Public Services. Consolidated revenues as of 12 months ending March 2025 totaled $13.8 billion. To learn how we can supercharge progress for you, visit Elka Ghudial, EMEA
Korea Herald
2 days ago
- Korea Herald
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer of advanced drug delivery technologies, announced today the acquisition of Focal Medical, Inc., a North Carolina-based biopharmaceutical company pioneering site-specific chemotherapy using iontophoresis. The acquisition represents a key step in Continuity's strategy to become a leader in device targeted therapeutics for intractable solid tumors. Founded by leading scientists and clinicians, Focal Medical has developed a proprietary platform that delivers chemotherapy directly to tumors using iontophoresis —this minimally-invasive technique utilizes a mild electrical current to drive therapeutic compounds into targeted tissues. This method enhances local drug concentration while minimizing systemic toxicity, a critical need in the treatment of pancreatic and other solid-tissue cancers. Focal Medical's lead product candidate, an iontophoresis device directed gemcitabine therapy for pancreatic cancer, has been cleared by the U.S. Food and Drug Administration (FDA) through an Investigational New Drug (IND) application. Phase 1b clinical trials are expected to begin later this year. "This is a transformative milestone for Continuity Biosciences," said Ramakrishna Venugopalan, PhD, MBA, Chief Executive Officer of Continuity Biosciences. "Focal Medical's approach to localized drug delivery aligns perfectly with our vision to improve bioavailability, reduce systemic exposure, and deliver better outcomes for patients. We are thrilled to bring this promising platform into our portfolio and into the clinic." Through the acquisition, Continuity Biosciences obtains Focal Medical's entire patent estate, iontophoresis technology platform and specialized equipment, scientific know-how, and licensing agreements with the University of North Carolina at Chapel Hill. In addition, key scientific staff and leadership from Focal will join Continuity, further enhancing its internal capabilities. A dedicated research and development facility in Cary, NC that supports ongoing platform and pipeline advancement is also part of the acquisition and will be expanded to support other delivery platforms. Visionary Founders Driving the Innovation Focal Medical was co-founded by: Their iontophoresis system is designed to deliver gemcitabine, an FDA-approved chemotherapy agent, directly into pancreatic tumors. Traditional systemic administration of gemcitabine is often limited by poor tumor penetration and significant toxicity. Focal's approach bypasses those limitations by delivering the drug directly to the tumor site with high precision and minimal systemic toxicity. "After nearly a decade of R&D, we are excited to join the Continuity Biosciences family," said Tony Voiers, Acting CEO of Focal Medical. "We are grateful to our founders, scientific collaborators, and investors who have helped us reach this pivotal point. Partnering with Continuity ensures that this novel therapy moves forward into the clinic where it has the potential to help patients facing one of the deadliest cancers." This acquisition reinforces Continuity Biosciences' commitment to building a diverse portfolio of clinically meaningful drug delivery platforms and signals a decisive move toward becoming a clinical-stage leader in site-specific therapy. About Continuity Biosciences Continuity Biosciences, LLC is a biopharmaceutical company developing advanced drug delivery technologies that address the limitations of conventional therapeutic administration. With operations in Bradenton, FL; Houston, TX; Raleigh, NC; and Torino, Italy, the company focuses on combination drug-device platforms for chronic and complex conditions. Visit:
Korea Herald
29-05-2025
- Korea Herald
Hybe to host Asia-wide music film festival in July
A music film festival will be held in 10 regions across Asia from July to August, Hybe announced Thursday. Under the title 'Hybe Cine Fest in Asia,' a series of concert films and a music visual featuring its four artists will come to cinemas, a joint effort with global distributor Trafalgar Releasing. Viewers will be able to sing along the reedited versions of concert films: 'Map of the Soul On:E' from BTS, 'Be the Sun – Seoul' from Seventeen, 'Act : Sweet Mirage Finale' from Tomorrow X Together, and 'Fate in Seoul' from Enhypen. A mash-up of 22 music videos from ten artists, including the aforementioned four as well as Le Sserafim, &Team, Boynextdoor, TWS, Illit and Katseye, will also be available on large screens with Romanized subtitles. The fest will kick off on July 10 and will run for four days in nine regions — Korea, Malaysia, Singapore, India, Indonesia, Thailand, Philippines, Hong Kong and Taiwan — and until Aug. 7 in Japan. At least one theater in each region will operate as a 'special location' where visitors can enjoy a range of experiences and purchase merchandises. The event was first held last year in 11 countries in Latin America and drew over 260,000 fans.
